drugset / Trial / NCT01522807

A Study Of Three PF-05190457 Formulations In Healthy Volunteers

NCT01522807 ↗

Phase 1 Completed 16 enrolled Pfizer
RandomizedCrossoverTriple-blindBasic science

Summary

The purpose of the study is to evaluate the plasma drug concentrations of three formulations of PF-05190457 after administration of single doses to healthy volunteers.

Timeline

Start
2011-09
Primary completion
2011-11
Completion
2011-11

Drugs

EvaluationDrugModalityDoseRoute
Subject PF-5190457 Small molecule 100 mg Oral